Rac1 has been shown to be overexpressed in lapatinib-resistant HER2 type breast cancer and is considered to be a viable therapeutic for sensitization of lapatinib resistant tumors (Wetterskog et al., 2014). Here, ERBB2 is linked to breast cancer.